Skip to main content
Top
Published in: Tumor Biology 1/2013

01-02-2013 | Research Article

Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population

Authors: Benyuan Deng, Fei Liu, Yonggang Wei, Limei Luo, Xi Chen, Lvnan Yan, Bo Li

Published in: Tumor Biology | Issue 1/2013

Login to get access

Abstract

P73, a p53 homolog, has some p53-like activities and plays an important role in modulating cell cycle, apoptosis, and DNA repair. A potentially functional dinucleotide polymorphism, G4C14-to-A4T14, has been identified in the 5′ untranslated region of exon 2 of the p73 gene, which may theoretically form a stem-loop structure and affect gene expression. We hypothesized that genetic variants in p73 may modify individual susceptibility to hepatocellular carcinoma (HCC). To test this hypothesis that these two common variants play a role in HCC susceptibility, we conducted a hospital-based case–control study of 476 HCC patients and 526 cancer-free controls in a Chinese population. The matrix-assisted laser desorption ionization time-of-flight mass spectrometry method was performed to detect these polymorphisms. The results showed that the genotype and allele frequencies of the p73 G4C14-A4T14 did not differ significantly between the HCC patients and the control group (all P values are above 0.05). However, with stratification analysis by age, sex, smoking status, drinking status, HBV carrier state, and family history of cancer, we found that the variant genotypes (GC/AT + AT/AT) of the p73 G4C14-A4T14 was associated with a significant increased risk of HCC among HbsAg-positive individuals (adjusted OR = 2.19, 95 % CI = 1.25–3.83) and among women (adjusted OR = 2.62, 95 % CI = 1.47, 4.66). These results suggest that the p73 G4C14-to-A4T14 dinucleotide polymorphism may play a role in the development of chronic HBV-infected HCC in the Chinese population, especially among women.
Literature
1.
go back to reference Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300–8.PubMedCrossRef Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300–8.PubMedCrossRef
2.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
go back to reference Heneghan MA, Johnson PJ, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer. 2003;34:19–26.PubMedCrossRef Heneghan MA, Johnson PJ, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer. 2003;34:19–26.PubMedCrossRef
4.
go back to reference Kato N, Ji G, Wang Y, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology. 2005;42:846–53.PubMedCrossRef Kato N, Ji G, Wang Y, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology. 2005;42:846–53.PubMedCrossRef
5.
go back to reference Kim YJ, Lee HS. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology. 2005;48:10–5.PubMedCrossRef Kim YJ, Lee HS. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology. 2005;48:10–5.PubMedCrossRef
6.
go back to reference Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404:99–103.PubMedCrossRef Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404:99–103.PubMedCrossRef
7.
go back to reference Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560–4.PubMedCrossRef Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560–4.PubMedCrossRef
8.
go back to reference Wang XQ, Ongkeko WM, Lau AW, et al. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res. 2001;61:1598–603.PubMed Wang XQ, Ongkeko WM, Lau AW, et al. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res. 2001;61:1598–603.PubMed
10.
go back to reference Cai YC, Yang GY, Nie Y, et al. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis. 2000;21:683–9.PubMedCrossRef Cai YC, Yang GY, Nie Y, et al. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis. 2000;21:683–9.PubMedCrossRef
11.
go back to reference Mai M, Yokomizo A, Qian C, et al. Activation of p73 silent allele in lung cancer. Cancer Res. 1998;58:2347–9.PubMed Mai M, Yokomizo A, Qian C, et al. Activation of p73 silent allele in lung cancer. Cancer Res. 1998;58:2347–9.PubMed
12.
go back to reference Nomoto S, Haruki N, Kondo M, et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 1998;58:1380–3.PubMed Nomoto S, Haruki N, Kondo M, et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 1998;58:1380–3.PubMed
13.
go back to reference Takahashi H, Ichimiya S, Nimura Y, et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 1998;58:2076–7.PubMed Takahashi H, Ichimiya S, Nimura Y, et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 1998;58:2076–7.PubMed
14.
go back to reference Peters MA, Janer M, Kolb S, et al. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate. 2001;48:292–6.PubMedCrossRef Peters MA, Janer M, Kolb S, et al. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate. 2001;48:292–6.PubMedCrossRef
15.
go back to reference Li Q, Athan ES, Wei M, et al. TP73 allelic expression in human brain and allele frequencies in Alzheimer’s disease. BMC Med Genet. 2004;5:14.PubMedCrossRef Li Q, Athan ES, Wei M, et al. TP73 allelic expression in human brain and allele frequencies in Alzheimer’s disease. BMC Med Genet. 2004;5:14.PubMedCrossRef
16.
go back to reference Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1q36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–19.PubMedCrossRef Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1q36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–19.PubMedCrossRef
17.
go back to reference Hu Z, Miao X, Ma H, et al. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer. 2005;114:455–60.PubMedCrossRef Hu Z, Miao X, Ma H, et al. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer. 2005;114:455–60.PubMedCrossRef
18.
go back to reference Hamajima N, Matsuo K, Suzuki T, et al. No association of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphism with the risk of digestive tract cancers in Japanese. Cancer Lett. 2002;181:81–5.PubMedCrossRef Hamajima N, Matsuo K, Suzuki T, et al. No association of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphism with the risk of digestive tract cancers in Japanese. Cancer Lett. 2002;181:81–5.PubMedCrossRef
19.
go back to reference Hiraki A, Matsuo K, Hamajima N, et al. Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. Asian Pac J Cancer Prev. 2003;4:107–12.PubMed Hiraki A, Matsuo K, Hamajima N, et al. Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. Asian Pac J Cancer Prev. 2003;4:107–12.PubMed
20.
go back to reference Huang XE, Hamajima N, Katsuda N, et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2000;10:307–11.CrossRef Huang XE, Hamajima N, Katsuda N, et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2000;10:307–11.CrossRef
21.
go back to reference Niwa Y, Hirose K, Matsuo K, et al. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett. 2005;219:183–90.PubMedCrossRef Niwa Y, Hirose K, Matsuo K, et al. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett. 2005;219:183–90.PubMedCrossRef
22.
go back to reference Li G, Sturgis EM, Wang LE, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2004;25:1911–6.PubMedCrossRef Li G, Sturgis EM, Wang LE, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2004;25:1911–6.PubMedCrossRef
23.
go back to reference Kang S, Wang DJ, Li WS, et al. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int J Gynecol Cancer. 2009;19:572–7.PubMedCrossRef Kang S, Wang DJ, Li WS, et al. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int J Gynecol Cancer. 2009;19:572–7.PubMedCrossRef
24.
go back to reference Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res. 2004;2:371–86.PubMed Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res. 2004;2:371–86.PubMed
25.
go back to reference Pozniak CD, Radinovic S, Yang A, et al. An anti-apoptotic role of the p53 family member, p73, during developmental neuron death. Science. 2000;289:304–6.PubMedCrossRef Pozniak CD, Radinovic S, Yang A, et al. An anti-apoptotic role of the p53 family member, p73, during developmental neuron death. Science. 2000;289:304–6.PubMedCrossRef
26.
go back to reference Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci. 2005;96:729–37.PubMedCrossRef Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci. 2005;96:729–37.PubMedCrossRef
27.
go back to reference Arfaoui AT, Ben Mahmoud LK, Ben Hmida A, et al. Relationship between p73 polymorphism and the immunohistochemical profile of the full-length (TAp73) and NH2-truncated (ΔNp73) isoforms in Tunisian patients. Appl Immunohistochem Mol Morphol. 2010;18:546–54.PubMedCrossRef Arfaoui AT, Ben Mahmoud LK, Ben Hmida A, et al. Relationship between p73 polymorphism and the immunohistochemical profile of the full-length (TAp73) and NH2-truncated (ΔNp73) isoforms in Tunisian patients. Appl Immunohistochem Mol Morphol. 2010;18:546–54.PubMedCrossRef
28.
go back to reference Li G, Wang LE, Chamberlain RM, et al. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res. 2004;64:6863–6.PubMedCrossRef Li G, Wang LE, Chamberlain RM, et al. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res. 2004;64:6863–6.PubMedCrossRef
29.
go back to reference Wang X, Zhang X, Qiu B, et al. MDM2 SNP309T > G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32:1172–8.PubMedCrossRef Wang X, Zhang X, Qiu B, et al. MDM2 SNP309T > G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32:1172–8.PubMedCrossRef
30.
go back to reference Li LM, Zeng XY, Ji L, et al. Association of XPC and XPG polymorphisms with the risk of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2010;18:271–5.PubMed Li LM, Zeng XY, Ji L, et al. Association of XPC and XPG polymorphisms with the risk of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2010;18:271–5.PubMed
31.
go back to reference Ryan BM, McManus R, Daly JS, et al. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer. 2001;85:1499–503.PubMedCrossRef Ryan BM, McManus R, Daly JS, et al. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer. 2001;85:1499–503.PubMedCrossRef
32.
go back to reference Ge H, Wang YM, Cao YY, et al. The p73 polymorphisms are not associated with susceptibility to esophageal squamous cell carcinoma in a high incidence region of China. Dis Esophagus. 2007;20:290–6.PubMedCrossRef Ge H, Wang YM, Cao YY, et al. The p73 polymorphisms are not associated with susceptibility to esophageal squamous cell carcinoma in a high incidence region of China. Dis Esophagus. 2007;20:290–6.PubMedCrossRef
Metadata
Title
Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population
Authors
Benyuan Deng
Fei Liu
Yonggang Wei
Limei Luo
Xi Chen
Lvnan Yan
Bo Li
Publication date
01-02-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0550-9

Other articles of this Issue 1/2013

Tumor Biology 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine